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ABSTRACT
CHAU T. TRUONG: Development and Evaluation of Quercetin Nanoparticles
and Hot Melt Cast Films for Retinal Neuroprotection
(Under the direction of Soumyajit Majumdar)
Purpose:
The aim of this study was to prepare optimized nanoparticles and hot melt cast films of
quercetin and to investigate the release and permeability profile across corneal
membranes.
Method:
Quercetin dissolved in DMSO was mixed with glycerin and added to the lipid phase of
either Glycerol monostearate or Miglyol 812® combined with Compritol ATO 888®. The
aqueous phase of Tween 80®, Poloxomer 188®, and water was added, and the premix was
homogenized, probe sonicated, and cooled to form the nanoparticles. Quercetin and
polyethylene oxide N10 were mixed, and the blend was pressed and melted to prepare the
films. Physicochemical profiles for nanoparticles were analyzed, and permeability across
rabbit cornea was studied for both formulations using side by side diffusion apparatuses.
Results:
The SLNs and NLCs demonstrated particle sizes of 65.4 and 46.1 r.mn, polydispersity
indices of 0.29 and 0.18, zeta potentials of -12.3 and -16.2 mV, assay of 78.4 and 86.6,
and entrapment efficiencies of 90.9and 93.4, respectively. Transcorneal flux of quercetin
nanoparticles, film and control were 0.036, 0.144, and 0.026, respectively.
Conclusion:
These results demonstrate that all formulations can be successfully employed for delivery
of quercetin into the eye through the topical route of administration, with films showing
significantly better transcorneal permeability.
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1. INTRODUCTION:
With increased age comes declining health conditions and increased
prevalence in diseases. Included in this broad category is the deterioration of vision due
to a variety of factors contributing to a number of ophthalmic diseases. These diseases
can include age-related macular degeneration, cataracts, diabetic retinopathy, and
glaucoma. According to statistics by the National Eye Institute, several millions of people
above the age of forty are affected by one of these conditions. From the total population
of those above age forty in the 2010 U.S. Census (n = 142,648,393), 36,883,997 adults
suffered from vision impairment due to all of the ophthalmic diseases listed above
combined (NEI “Prevalence”, 2016). This is approximately over a quarter (25.9%) of
adults over age forty who are affected with vision impairment. As age increases, the
prevalence rates of all vision impairment also increase, rising significantly around ages
75-79 in all ethnicities, as shown in Figure 1.

Figure 1. 2010 U.S. Prevalence Rates: All Vision Impairment
Source: National Eye Institute. All Vision Impairment. Available at:
https://nei.nih.gov/eyedata/vision_impaired#1. Accessed March 27, 2017.
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Over the course of ten years, starting from the year 2000, the prevalence of vision
impairment has increased by almost 130% (NEI “Vision”, 2016). These trends are
expected to continue with each subsequent year so that by the year 2030, there will be
almost a two-fold increase in prevalence of vision impairment compared to that in 2010,
and by 2050, there will be more than a 3-fold increase in prevalence, as shown in Table 1
and Figure 2.
Table 1. Table Projections for Vision Impairment (2010-2030-2050)
Year

All

White

Black

Hispanic

Other

2010

4,195,966

3,398,977

330,644

290,781

175,564

2030

7,169,680

5,277,689

618,110

840,497

433,383

2050

13,026,870

9,019,189

1,047,986

2,000,853

958,842

Total
Population

142,648,393

103,846,437

15,190,777

14,901,369

8,709,810

Source: National Eye Institute. Vision Impairment Tables. Available at:
https://nei.nih.gov/ eyedata/vision_impaired/tables. Accessed March 27, 2017.

Figure 2. Chart Projections for Vision Impairment (2010-2030-2050)
Source: National Eye Institute. All Vision Impairment. Available at:
https://nei.nih.gov/eyedata/vision_impaired#1. Accessed March 27, 2017.
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One cause of vision impairment is due to uncontrolled exposure to
reactive oxidative species, or ROS. These are species that are produced naturally in the
body as a byproduct of adenosine triphosphate, or ATP, production, the energy source
that is used for every day function and processes (Prunty, 2015). They are free radicals
that contain oxygen and are the most common type produced in tissues (NCI, 2014).
They can affect cells by damaging important cellular components, such as DNA,
proteins, and membranes. The mitochondria, an efficient organelle found abundantly in
the body’s cells and tissues, produce the largest quantities of ROS as it is the largest
contributor to ATP synthesis (90% of the body’s energy) [UMDF, 2017]. The body has
natural antioxidant mechanisms to protect against ROS, but when ROS are overproduced,
these mechanisms are overwhelmed (Prunty, 2015). This leads to oxidative stress
cascades on cells and tissues, which causes them to become damaged and eventually die
off. In the eye, ROS damage the cells of the retina, which plays an important role in
converting visual images into electrical impulses for the brain to interpret. As the
photoreceptor cells of the retina die off, vision worsens as the eye has less capability to
convert those images to impulses. The longer the period of exposure to ROS, the more
damage is done to the retina. Prolonged damage to the retina exacerbates retinal
degradation and degeneration, further impairing vision and may even lead to permanent
blindness. This is why as a person ages, their vision becomes progressively worse.
A protective measure against ROS is the use of antioxidant treatments.
Antioxidants can be used to slow the rate of retinal degradation by counteracting damage
from the reactive oxidative species. The body produces some antioxidants endogenously,
but they can also be obtained outside of the body. They can be found in a variety of
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antioxidant-rich foods, such as fruits, leafy green vegetables, and grains, and can also be
obtained through dietary supplements. These include carotenoids like beta-carotene,
lycopene, and vitamins A, C, and E (NCI, 2014). There are a variety of substances that
act as antioxidants, like the ones mentioned before, in addition to glutathione, coenzyme
Q10, lipoic acid, flavonoids, phenols, polyphenols, phytoestrogens, etc., all having
different properties and roles against ROS (Harvard, 2017). In the case of preventing
retinal degradation to improve outcomes in terms of vision integrity and function,
antioxidants can be employed to protect against the damage from reactive oxidative
species. However, because of physiological barriers, antioxidants cannot simply be taken
orally and expected to be able to reach its target, i.e. the retina, to enact its protection.
This is due to the way that the eye is structured. The retina is located in the
posterior chamber of the eye, which is generally challenging to access (Kaufman, 2011).
There is a blood-retinal barrier, which is formed by retinal capillaries and tight junctions
of retinal vascular endothelium that limit drug access from the general circulation. If
taken orally, antioxidants would face a number of problems in trying to reach the retina.
Firstly, it would undergo first-pass metabolism to which oral drugs are susceptible. This
limits the amount of drug available to be absorbed and to be effective in the body.
Secondly, dietary antioxidants, such as flavonoids, tend to be poorly soluble. Low
solubility negatively affects dissolution rates, which limits how much of the drug can be
absorbed into the circulatory system. This, in turn, limits the bioavailability of the drug
for use in the body. Lastly, even if the drug were able to be absorbed into the circulatory
system, not only would it be severely limited in terms of bioavailability, but also it would
not be able to effectively reach its target due to the blood-retina barrier and lack of
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circulation in the back of the eye. Thus, taking antioxidants as an oral dosage form would
not be a viable option when targeting the retina.
Drug administration directly to the eye would be a more effective route
compared to oral dosing. There are several ocular dosage forms and drug delivery
systems, though these too are not without their challenges (see Figure 3 and Table 2).
Some routes of administration include topical and injectable. Drugs administered through
the topical route are most commonly in the form of eye drops, are noninvasive, and have
high patient compliance. These are generally better for delivery to the anterior part of the
eye. This is because there are several barriers that prevent absorption towards the back of
the eye. Firstly, blinking and the production of tears can quickly wash away the drug and
clear it from the eye. In fact, the majority of topically administered dosages are washed
away within 15-30 seconds after instillation (Gaudana, 2010). Thus, very little of the drug
is in contact with the eye long enough to be absorbed, accounting for less than 5% of the
applied dose. Secondly, even if the drug were absorbed from the surface of the eye, it
would have to pass through all layers of cornea, including the epithelium, stroma, and
endothelium, to reach the aqueous humor, the fluid that fills the anterior part of the eye.
Each layer has alternating hydrophilicity and lipophilicity that the drug must be
compatible with in order to pass through the layers. The epithelium is lipophilic and so
resists the permeation of hydrophilic drugs. The stroma is hydrophilic and resists the
permeation of lipophilic drugs. The endothelium is similar to the epithelium in that it is
lipophilic and resists hydrophilic drugs (Kaufman, 2011). In order to permeate through
the corneal layers, the drug must be amphipathic, meaning it must possess both lipophilic
and hydrophilic characteristics to pass through the respective layers. A way to bypass this
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requirement would be to deliver the drug via injection, specifically intravitreal injections.
Injections bypass the mechanical barriers, i.e. the different layers of the eye, to deliver the
drug directly to the posterior segment of the eye into the vitreous humor (Gaudana,
2010). It is a more effective route compared to topical administration in terms of drug
delivery to the back of the eye, but it is not very patient compliant as it is very invasive.
Additionally, because drug distribution in the vitreous humor is not uniform due to lack
of circulation, only small molecules can rapidly distribute through the vitreous humor as
distribution of larger molecules is limited.

Figure 3. Routes of Administration for Ocular Drug Delivery
Source: Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery.
The AAPS Journal. 2010;12(3):348-360.

6

7

BA = bioavailability, BAB = blood–aqueous barrier, BRB = blood–retinal barrier, AMD = age-related macular degeneration, DME = diabetic
macular edema, BRVO = branched retinal vein occlusion, CRVO = central retinal vein occlusion, RVO = retinal vein occlusion, CME =
cystoid macular edema, UME = uveitic macular edema, CMV = cytomegalovirus, IOP = intraocular pressure, TASS = toxic anterior segment
syndrome, TECDS = toxic endothelial cell destruction syndrome, RPE = retinal pigmented epithelium, PU = posterior uveitis

Source: Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. The AAPS Journal.
2010;12(3):348-360.

Table 2. Benefits and Challenges of Ocular Routes of Administration

Many studies over the past few years have demonstrated the effectiveness
of nanotechnology in ocular drug delivery. In one study, the administration of very small
sized molecules (20 nm) of gold resulted in the particles readily passing through the
blood-retinal barrier, which, as stated before, is a major barrier in getting the drug to the
retina, and distributing in all the retinal layers without cytotoxicity (Gaudana, 2010).
Increased penetrance and better distribution of small molecules, specifically
nanoparticles, in the posterior segment of the eye would increase bioavailability and
consequently pharmacological activity, which in turn can improve health outcomes. In
this research, two nanoparticle formulations, solid lipid nanoparticles and nanostructured
lipid carriers, were being investigated for efficacy in delivering quercetin, an antioxidant
flavonoid, into the eye for retinal neuroprotection, compared against hot melt cast films.
Many studies have been performed with quercetin nanoparticles targeted at various areas
of the body and through different dosage routes, but to our knowledge, there are no
known studies aimed for delivery into the eye. The advantages of using a topical
administration route are high patient compliance and ease of modification to improve
drug solubility, and these paired with the advantages of nanoparticle formulations makes
them promising candidates for ocular drug delivery.

1.1 Solid Lipid Nanoparticles:
Solid lipid nanoparticles, or SLNs, are dispersions that contain particles
that have an average size of 500 nanometers or smaller and that contain low microparticle
content (Mehnert, 2012). These nanoparticle dispersions are commonly and effectively
produced via a high pressure homogenization process. As the name suggests, solid lipid
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nanoparticle formulations use solid lipids, such as trilaurin, tripalmitin, glyceryl
monostearate, glyceryl behenate, and stearic acid, for the lipid phase instead of lipid oils,
primarily as a means to control drug release and to increase stability in vivo. Drugs
encapsulated in a solid lipid have considerably lower mobility, and thus slower drug
release from the lipids, compared to drugs encapsulated in liquid oil. The solid lipids also
remain in a solid form at body temperature, which contributes to higher stability of the
delivery system in vivo (Beloqui, 2016). In addition to controlled drug release, SLNs
have many other advantages as a drug delivery system. These advantages include
increased drug stability, high drug payload, ability to incorporate lipophilic and
hydrophilic drugs, no biotoxicity or use of organic solvents, and ease in large scale
production and sterilization (Mehnert, 2012).
The general formulation of SLNs includes a lipid phase containing the
solid lipid and drug, an aqueous phase, and emulsifiers to stabilize the lipid dispersion
and to prevent particle agglomeration. Formulations can also include cyclodextrins,
which are cyclic oligosaccharides with hydrophobic inner cores and hydrophilic outer
surfaces. Many studies have been performed to demonstrate that the addition of
cyclodextrins is beneficial in the formulation process (Adelli “Effect”, 2015; Srirangam,
2012). The use of cyclodextrins in the SLN formulations not only enhances the solubility
of lipophilic drugs by forming soluble complexes with the drugs (i.e., encapsulating the
drug in the core), but it also improves drug permeability across biological membranes by
increasing the availability of drug molecules at the surface of the membranes (Adelli
“Effect”, 2015). These advantages, in turn, increase the bioavailability and consequently,
the action of the drug at the target site.
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There are many different methods and techniques that can be used to
produce SLN formulations (Mehnert, 2012). Some examples include high shear
homogenization and ultrasound, high pressure homogenization, solvent emulsification
and evaporation, and microemulsion dilutions. Under the high pressure homogenization
method, there are two different techniques: hot homogenization and cold
homogenization. A schematic of these two techniques is shown below in Figure 4. In this
research study, the hot high pressure homogenization technique was used, which
produces a nanoemulsion that sports the advantages of highly impeded lipid
crystallization and prolonged storage as a supercooled melt.

Figure 4. Hot vs. Cold Homogenization Techniques
Source: Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and
applications. Advanced Drug Delivery Reviews 2012; 64:83-101.
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In characterizing SLN formulations, the goal parameters are small and
uniform particle sizes (less than 500 nm), low polydispersity index, and high magnitude
of zeta potential. These specific parameters would ensure the most stable and
homogeneously distributed formulation. Studies suggest that smaller (nanoparticle) sizes
have slightly faster release rates when compared to larger (microparticle) sizes (Dan,
2016). Polydispersity index measures the degree of non-uniformity, or rather, the
deviation from uniformity in a dispersion. A low value for PDI would indicate a more
evenly distributed formulation with uniform particle sizes. Zeta potential measures the
magnitude of electric repulsion between particles. A high magnitude for zeta potential
would mean that there is strong electric repulsion between the particles, which would
decrease the likelihood of particle aggregation in the dispersion, and thus, would increase
the stability of the formulation.

1.2 Nanostructured Lipid Carriers:
Nanostructured lipid carriers, or NLCs, constitute another drug delivery
system with controlled drug release from nanoparticles. Not only have NLCs been shown
to improve drug permeation and aqueous solubility of drugs, but also these formulations
have demonstrated to increase drug retention and more importantly, to enhance the
antioxidant and anti-inflammatory effects of quercetin (Beloqui, 2016). The
differentiating characteristic of NLCs from SLNs is the incorporation of a liquid lipid,
such as caprylic or capric triglycerides, lauroyl polyoxyglycerides, monoacylglycerols,
and soy lecithin, in the solid lipid matrix, which results in an unstructured solid lipid
matrix. The use of a liquid lipid in the lipid matrix increases the amount of openings and
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gaps in the solid matrix, allowing for more of the drug to be encapsulated into the
nanoparticles as well as increasing the drug release rate by increasing the surface
permeability of the nanoparticles. Comparatively, drug release through the solid lipid is
slower and more limited than the drug release through the liquid lipid due to the lower
solubility of the drug in the solid lipid (Dan, 2016). The incorporation of the liquid lipid
improves drug solubility in the nanoparticles and increases the rate and amount of drug
release while still controlling how much is released into the body at a time. The lipid
blends can be mixed in any ratio from 70:30 up to 99.9:0.1, solid lipid to liquid lipid
(Beloqui, 2016). Otherwise, the general formulation is the same as that of SLNs. The
NLC formulation consists of a lipid phase which contains the drug, an aqueous phase,
and surfactants accounting for about 1.5-5% w/v of the formulation.
NLCs can be made using a variety of methods, such as microemulsification and solvent displacement, but similar to SLNs, the most preferred method
is high pressure homogenization, specifically hot homogenization, as it does not require
the use of solvents during the preparation process and can be easily implemented in large
scale production. Due to the presence of water in these formulations, physical instability
caused by microbial growth is a major concern. To circumvent this problem and to
preserve ideal nanoparticle characteristics, the formulation can either be lyophilized to
remove water content and form a solid formulation, or a preservative can be added to the
formulation to inhibit microbial growth while maintaining a liquid formulation. Criteria
for a lyophilized formulation include short reconstitution time, easy resuspension in
water, no changes to particle size distribution of nanoparticles, and preserved drug
activity. To prevent aggregation of the lyophilized particles, a cryoprotectant is required.
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One such cryoprotectant shown in studies to effectively prevent particle aggregation
while preserving the stability of the nanoparticle shell structure is trehalose. However,
caution should be taken when using a lyophilization method as the use of cyroprotectants
often implies alteration of initial nanoparticle surface properties. Other preservation
methods may be more favored and advised in this case, such as the use of a preservative
while maintaining the water content of the formulation. This method ensures that there
are minimal changes to the nanoparticle surface properties (e.g., zeta potential). The ideal
preservative should be highly hydrophilic, non-ionic, and have little affinity to the
particle surface.
The goal parameters of NLCs are also the same as those for SLNs. The
desired formulation should have small (less than 500 nanometers) and uniform particle
sizes, low polydispersity index, and high magnitude of zeta potential to ensure the
greatest stability and homogeneous distribution.

1.3 Hot Melt Cast Films:
Hot melt cast films are yet another drug delivery system that is used for
improving bioavailability of poorly soluble drugs. They are solid molecular dispersions
of a drug or active pharmaceutical ingredient in a polymeric matrix that provide
controlled and sustained drug release while eliminating the use of solvents in the
preparation process (Repka, 2007). These formulations have the advantages of being
quicker and more efficient to produce as well as increased efficiency of drug delivery.
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The general formulation for hot melt films includes a blend of the active
ingredient or drug, a thermoplastic polymeric carrier, and other processing aids like
plasticizers or antioxidants. This blend is then heated and softened before being pressed
in a die to form the film. This method is known as hot melt extrusion, or HME, when an
extruder is used, and it can be used to form a variety of other dosage forms as well, such
as granules, pellets, tablets, capsules, and implants. There are specific criteria for
materials used in the HME process, a major one being thermal stability as the materials
must be able to withstand the high temperatures at which the process is performed
without degrading (Crowley, 2007). They must also be able to easily deform while in the
extruder and solidify upon exiting the extruder to form a solid dosage form.
In regards to the active pharmaceutical ingredients, the drug contained in
the dosage form may be dispersed in the polymeric matrix as undissolved particles, a
solid solution, or some combination of both. Because of this, the dosage form may be a
solid dispersion system, in which the drug is undissolved and dispersed in the carrier
matrix, or a solid solution system, in which the drug is dissolved in the carrier matrix.
Solid dispersions have the advantages of being more stable and more easily produced
compared to solid solutions. However, solid solutions have the advantage of exhibiting
potentially higher bioavailability of poorly soluble drugs over solid dispersions. The
properties of the drug can also affect the functionality of other materials used in the
formulation. The drug can negatively affect the formulation by decreasing the viscosity
or inhibiting the hardening of the matrix, which results in a dosage form that will be
poorly handled and unusable. On the other hand, the drug could positively affect the
formulation by lowering the glass transition temperature of the polymeric carrier, which
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can improve processing conditions. Thus, the drug should be compatible with the other
ingredients used in the formulation in order to yield a good dosage form.
A second major component of the formulation is the carrier, which is
generally a polymer, a low melting point wax, or a mixture of low melting point
substances in which the drug or active pharmaceutical ingredient is embedded. The
compatibility of the drug and carrier compounds should be taken into account as there is
the possibility of the formation of a eutectic mixture when mixing a low melting drug
with a low melting carrier, which would result in a dosage form that would not be able to
solidify. The physical and chemical properties of the carriers can also highly affect the
drug release from the dosage form. Drug release mechanisms differ depending on the
type of carrier used. Water insoluble carriers exhibit a diffusion controlled drug release
rate while water soluble carriers exhibit a diffusion and erosion drug release mechanism.
Ionic or pH dependent carriers can be used to achieve zero-order or site-specific drug
release. Functional excipients can be added to the carrier to modulate the rate of drug
release as well, by altering either the porosity, tortuosity, viscosity, or rate of
disintegration of the polymeric matrix and the resulting dosage form.
Plasticizers are the third important component of the formulation.
Plasticizers are low molecular weight compounds that can have two roles in the
formulation process: increase polymeric flexibility and decrease processing temperatures.
They can be used to soften the polymers to make the resulting dosage form more flexible.
They can also improve processing conditions by decreasing the glass transition
temperature and melt viscosity of a polymer by increasing the free volume between
polymer chains while decreasing the ease of their movement with respect to each other,
15

which allows the HME process to be conducted at lower temperatures and with less
energy. This improves the drug and carrier stability by reducing their degradation.
Plasticizers used in the formulation should have good efficiency, stability, polymerplasticizer compatibility, and permanence, as these can affect the physical and
mechanical properties as well as the drug release rate of the dosage form.
Lastly, there are other processing aids, like antioxidants, acid receptors,
and light absorbers, which can be used to improve the stability of the other components
and the overall formulation. Antioxidants, which can be either preventive or chainbreaking, are used to protect the compounds against free radicals and oxidative
degradation. Preventive antioxidants prevent the initiation of free radical chain reactions
while chain breaking antioxidants inhibit free radical chain reactions. Preventive
antioxidants include reducing agents, which preferentially undergo oxidation and thus
protect the other compounds from oxidative damage, and chelating agents, which form
stable complexes with the metal ions to prevent them from catalyzing the formation of
free radicals and thus decrease the number of free radicals produced. Chain breaking
antioxidants include hindered phenols and aromatic amines, which have very weak O-H
and N-H bonds, respectively, that will undergo a higher rate of oxidation and thus reduce
oxidation of the other formulation components. Other processing aids can be used to
improve processing conditions, such as glyceryl monostearate, which can act as a thermal
lubricant, and Vitamin E TPGS, which can enhance drug absorption.
The main goal parameters for hot melt cast films are homogenous
distribution of the drug in the polymeric matrix, high stability of the drug, polymer, and
any additives, and good rate and quantity of drug release.
16

1.4 Quercetin:
Quercetin, which has the chemical name of 2-(3,4-Dihydroxyphenyl)3,5,7-trihydroxy-4H-1-benzopyran-4-one, is a bioflavonoid aglycone, specifically of the
flavonol subclass, meaning that it has a 3-hydroxyflavone backbone and lacks attached
sugars, as shown in Figure 5 (Kelly, 2011).

Figure 5. Quercetin Structure
Source: Quercetin [product insert]. Ann Arbor, MI: Cayman
Chemical Company; 2016.
It is a crystalline solid that has a bright citron yellow color. It is lipophilic and
hydrophobic in nature so its solubility in water is poor to nonexistent (poor in hot water
and entirely insoluble in cold water). A way to improve its solubility in water is to
convert it to a glycoside. This can be done by replacing one of the hydroxyl groups,
commonly the one at position 3, with a glycosyl group, which can be any sugar such as
glucose, rhamnose, or rutinose (see Figure 6). A glycoside group at position 3 is known
as isoquercitin. The addition of a glycosyl group changes the chemical properties of the
drug, including solubility, absorption, and in vivo effects. Specifically, the addition of the
glycosyl group increases the water solubility of quercetin.
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Figure 6. Quercetin-3-O-β-Glucoside Structure
Source: Bentz AB. Review of quercetin: chemistry, antioxidant properties, and
bioavailability. Journal of Young Investigators 2009.
Otherwise, if quercetin were to be solubilized in an aqueous buffer, it would first need to
be dissolved in DMSO and then diluted with the aqueous buffer. Quercetin is rather well
soluble in organic solvents, such as ethanol, acetic acid, dimethyl formamide, and
dimethyl sulfoxide. In ethanol, quercetin has a solubility of 2 mg/mL whereas in DMF
and DMSO, it has a solubility of 30 mg/mL (up to 100 mM) [Cayman, 2016; Abcam,
2017].
Quercetin is found in a variety of foods, such as onions, shallots, apples,
berries, grapes, and tea leaves, as well as in some medicinal botanicals, such as Ginkgo
biloba, Hypericum perforatum (St. John’s wort), and Sambucus canadensis (elder)
[Kelly, 2011]. It is commercially available as dietary supplements and as additives to
foods and beverages. It has many potential uses, as demonstrated in several test tube
studies, though more research is required in humans to prove efficacy. Quercetin has
been demonstrated to prevent immune cells from releasing histamine, which is
responsible for allergic reactions, as well as to prevent free radicals from activating
transcription factors that generate pro-inflammatory cytokines, making it a good
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candidate for reducing symptoms of allergies and inflammatory conditions (Erhlich,
2015; Bentz, 2009). In respect to heart disease and hypertension, various studies,
including test tube, animal, and population-based studies, suggest that the flavonoids
found in red wine like quercetin may reduce blood pressure and the risk of
atherosclerosis. It can also help in hypercholesterolemia by reducing LDL levels. It does
so by exhibiting a potent inhibitory effect on lipid absorption in the gastrointestinal tract,
and it also helps eliminate lipids from the body by enhancing lipid metabolism in the
liver, which ultimately protects the body against damage by LDL cholesterol
(Flavonoids, 2017). Quercetin has also been shown to exhibit antitumor characteristics in
terms of inhibiting the growth of cancer cells and tumors. In one study, it was suggested
to be more efficacious in tumor growth inhibition than resveratrol (Erhlich, 2015). These
are only a few of the numerous clinical indications in which quercetin may have
beneficial effects.
In respect to this research, the most important characteristic of quercetin,
however, is its antioxidant properties. Quercetin is a strong antioxidant that can bind
transition metal ions, scavenge free radicals, and increase glutathione levels (Bentz,
2009). Specifically it can inhibit lipid peroxidation, which is the process by which
unsaturated fatty acids are converted to free radicals by hydrogen extraction. When the
free radicals are oxidized by molecular oxygen, lipid peroxy radicals are created, which
then extract hydrogen molecules from other unsaturated fatty acids and produce more
free radicals in an amplifying cascade process. Trace amounts of transition metal ions can
catalyze this process. The overproduction of free radicals over a prolonged period of time
can lead to extensive damage to various body tissues, including those of the heart, brain,
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eye, and associated structures. Quercetin not only hinders the production of free radicals
significantly by mopping up any transition metal ions, but also it greatly reduces the
number of free radicals already made in the body by scavenging and neutralizing them.
Additionally, it can increase glutathione levels in the brain to protect neurons from
oxidative damage by competitively converting hydrogen peroxide to oxygen and water,
instead of allowing superoxide dismutase to convert it to a superoxide radical. This
allows it to reduce oxidative stress in the body, protecting it from a myriad of ailments,
such as cardiovascular disorders, neurodegenerative diseases, atherosclerosis, chronic
inflammation, and retinal degeneration.
In terms of safety and toxicity, quercetin has been demonstrated to be well
tolerated in human studies. Doses as high as 1,000 mg/day were administered for several
months, and no adverse effects on liver and kidney functions, hematology, or serum
electrolytes were produced as a result (Kelly, 2011). However, one potentially significant
concern with respect to toxicity is the concomitant use of digoxin with high doses of
quercetin, which has been shown to have a lethal effect in one pig study. More research is
needed to determine safe dosage levels of quercetin when used concomitantly, but for the
purpose of our research, the dose of quercetin used was deemed to be safe for human use.
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2. MATERIALS AND METHODS:
2.1 Materials:
Quercetin was purchased from Tocris Bioscience. Glycerol monostearate
and Compritol ATO 888® were graciously donated by Gattefossé. Miglyol 812® was
purchased from Condea. Tween 80 and methyl-beta-cyclodextrin were purchased from
Acros Organic. Poloxamer 188 was purchased from Spectrum. Glycerin was purchased
from PCCA. Acetonitrile and dimethyl sulfoxide were purchased from Fisher Chemical.
Whole rabbit eye globes were purchased from Pel-Freez Biologics. The rabbit eye globes
were dissected in lab to collect the corneas for use in the permeability studies.

2.2 Methods:
Solid Lipid Nanoparticles:
Quercetin solid lipid nanoparticles, or SLNs, were prepared by probe
sonication method. The lipid phase was prepared with a solid lipid (0.7% w/v Glycerol
monostearate) in combination with 1.3% w/v Compritol ATO 888® and heated on a hot
plate at 80oC. Quercetin was dissolved in 100 µL of dimethyl sulfoxide and added to
2.25% w/v glycerin. This mixture was added to the melted lipid phase. The aqueous
phase was prepared using 0.75% w/v Tween 80®, Poloxomer 188®, and filtered water
and heated on the hot plate at 80oC. The aqueous phase was then added to the lipid phase
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while stirring at 600 rpm for 2 minutes. The final concentration of quercetin was 0.1%
w/v. The premix was homogenized with an Ultra-Turrax® at 16,000 rpm for 3 minutes to
form a coarse emulsion. This coarse emulsion was then subjected to probe sonication at a
15-second pulse rate for 3 minutes. The final emulsion was allowed to cool to form the
nanoparticles.
Nanostructured Lipid Carriers:
Quercetin nanostructured lipid carriers, or NLCs, were also prepared by
probe sonication method. The method is almost exactly the same as that for the SLN
formulation, except that the lipid phase was prepared with a liquid lipid (0.7% w/v
Miglyol 812®) in combination with 1.3% w/v Compritol ATO 888®, which was then
heated on a hot plate at 80oC. Quercetin was dissolved in 100 µL of dimethyl sulfoxide
and added to 2.25% w/v glycerin. This mixture was then added to the melted lipid phase.
The aqueous phase was prepared using 0.75% w/v Tween 80®, Poloxomer 188®, and
filtered water and heated on the hot plate at 80oC. The aqueous phase was added to the
lipid phase while stirring at 600 rpm for 2 minutes. The final concentration of quercetin
was 0.1% w/v. The premix was homogenized with an Ultra-Turrax® at 16,000 rpm for 3
minutes to form a coarse emulsion, which was then subjected to probe sonication at a 15second pulse rate for 3 minutes. The final emulsion was allowed to cool to form the
nanoparticles.
Hot Melt Cast Films:
Quercetin films were prepared by melt-cast method. Polyethylene oxide
N10 was used as the matrix forming polymer. Quercetin and PEO N10 were mixed via
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geometric dilution to prepare the physical mixture. The drug load in the film was 10%
w/w. A 10 mm die was placed over a brass plate and heated on a hot plate at 75°C for at
least one minute. The physical mixture was poured into the center of the die and
compressed for a few seconds to form a flat matrix surface. The film was heated on the
hot plate for an additional minute so that the mixture was completely melted and then
removed to cool. When completely cooled, the film was cut to collect samples that
weighed approximately 8 mg each.
Characterization of Nanoparticles:
Mobile phase of acetonitrile:water (ACN:H2O, 40:60) was prepared.
Quercetin was dissolved in dimethyl sulfoxide (DMSO) to make a 1 mg/mL stock
solution for the standards. Varying volumes of the stock solution were diluted with the
mobile phase to make standards of the following concentrations: 1 μg, 2 μg, 5 μg, 10 μg,
and 20 μg. The standards were analyzed using UV analysis at a wavelength of 369 nm to
determine the light absorbance trend, or calibration curve, of quercetin to which the
nanoparticle emulsions will be compared.
The SLN and NLC formulations were diluted 500 times with purified
water and analyzed using a zetasizer (Malvern Instruments, Ltd.) to determine the size,
polydispersity index, and zeta potential of the particles. The goal was to have small
particle sizes, low polydispersity index, and high magnitude of zeta potential for the most
stable and homogeneous formulation.
Entrapment efficiency, which is a measure of how much drug is entrapped
in the nanoparticles, was performed by centrifuging 500 μL of each formulation with a
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filter for 15 minutes. 100 μL of the centrifuged filtrate was drawn, diluted with 900 μL of
the mobile phase, and then vortexed to ensure thorough and homogeneous mixing.
Assay was performed to determine quercetin content in the nanoparticles.
For each formulation, 100 μL of formulation were added to 900 μL of a mixture of
DMSO and methanol (50:50) and sonicated for 10 minutes. After sonication, the mixture
was centrifuged for 15 minutes. From this, 100 μL of the supernatant was drawn and
diluted with 900 μL of the mobile phase before being vortexed to ensure thorough and
homogeneous mixing.
All samples collected from entrapment efficiency and assays were
analyzed in triplicates using HPLC-UV method with a Kinetex® 5 μm EVO C18 100 Å
LC column (250 x 4.6 mm).
Characterization of Films:
Mobile phase of acetonitrile:water (ACN:H2O, 40:60) was prepared.
Quercetin was dissolved in dimethyl sulfoxide (DMSO) to make a 1 mg/mL stock
solution for the standards. Varying volumes of the stock solution were diluted with
acetonitrile to make standards of the following concentrations: 1 μg, 2 μg, 5 μg, 10 μg,
and 20 μg. The standards were analyzed using UV analysis at a wavelength of 369 nm to
determine the calibration curve of quercetin to which the film samples will be compared.
Samples of approximately 8 mg were cut from quercetin films and added
to 2 mL of acetonitrile. This mixture was then sonicated for 5 minutes until the film was
completely dissolved. After sonication, the stock was diluted by a factor of 20. All
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samples were collected and analyzed in triplicates using UV analysis at a wavelength of
369 nm.
Permeability Studies:
Release and permeability of quercetin from the nanoparticles were studied
using a vertical dialysis cassette with a 10,000 Dalton MWCO membrane. Isotonic
phosphate buffer saline, or IPBS, was made with 5% methyl-beta-cyclodextrin. IPBS
served as the receiver medium. 18 mL of IPBS was filled into the vial, and 1 mL of
formulation was filled into the cassette. Measurements were taken at 15, 30, 60, 90, 120,
150, and 180 minute time points, at which time 1 mL of the receiver medium was drawn
and 1 mL of IPBS was added into the vial. All samples collected were analyzed in
triplicates under HPLC-UV method.
Permeability of quercetin from NLCs and films was studied using fresh
rabbit cornea in a side-by-side diffusion apparatus, maintained at 34°C using a circulating
water bath. IPBS with 5% methyl-beta-cyclodextrin was made. Spectra/Por® membrane
(10,000 Daltons MWCO) were cut and soaked in IPBS for 30 minutes. Side-by-side
diffusion cells were set up so that the fresh rabbit cornea and Spectra/Por® membrane
were sandwiched between the cells. For the film studies, the films were cut to
approximately 45 mg and wetted with IPBS. They were then sandwiched between the
rabbit cornea and Spectra/Por® membrane, in the following order: donor
cellSpectra/Por® membranequercetin filmcornearecipient cell (see Figure 7).
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Figure 7. Side-by-Side Diffusion Apparatus Setup
Source: Adelli GR, Hingorani T, Punyamurthula N, et al. Evaluation of topical hesperetin
matrix film for back-of-the-eye delivery. European Journal of Pharmaceutics and
Biopharmaceutics 2015; 92:74-82.
Both the donor and recipient cells for the film studies were filled with 3.2 mL of IPBS.
For the NLC formulations and the control, which was 3 mg of pure quercetin mixed with
IPBS, 3.2 mL of each formulation were added into their respective donor cells, and 3.2
mL of IPBS were added to the recipient cells. Measurements were taken at 30, 60, 90,
120, 150, and 180 minute time points. After flushing a few times to mix the receiver
medium, 0.6 mL samples were drawn from the recipient cell, except for the films, for
which samples were collected from both donor and recipient cells, and 0.6 mL of IPBS
was added to the cells to replace the volume removed. The samples were analyzed in
triplicates using UV analysis at a wavelength of 369 nm.
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3. RESULTS:
3.1 Characterizations of Nanoparticles and Films:
The solid lipid nanoparticles demonstrated an average particle size of 65.4
r.nm, polydispersity index of 0.29, and zeta potential of -12.3 mV. Assay and entrapment
efficiency results were 78.4 ± 1.6% and 90.9 ± 0.3%, respectively. Drug release across
the Spectra/Por® membrane was 33.3 ± 1.5%. These parameters are summarized below
in Table 3. Particle size distribution is shown in Figure 8.
Table 3. Physicochemical Characterization of SLN Formulations
Parameters
Particle Size (r.nm)
Polydispersity Index
Zeta Potential (mV)
Assay
Entrapment Efficiency
% Release across
Spectra/Por® Membrane

Solid Lipid Nanoparticles
65.4
0.29
-12.3
78.4 ± 1.6
90.9 ± 0.3
33.3 ± 1.5

Figure 8. SLN Particle Size Distribution by Intensity
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The nanostructured lipid carriers demonstrated an average particle size of
46.1 r.nm, polydispersity index of 0.18, and zeta potential of -16.2 mV. Assay and
entrapment efficiency results were 86.6 ± 0.2% and 93.4 ± 0.1%, respectively. Drug
release across the Spectra/Por® membrane was 47.1 ± 7.9%. These parameters are
summarized below in Table 4, and particle size distribution is shown below in Figure 9.
The comparison of the particle size distributions for the SLN and NLC formulations is
shown below in Figure 10.

Table 4. Physicochemical Characterization of NLC Formulations
Parameters
Particle Size (r.nm)
Polydispersity Index
Zeta Potential (mV)
Assay
Entrapment Efficiency
% Release across
Spectra/Por® Membrane

Nanostructured Lipid Carriers
46.1
0.18
-16.2
86.6 ± 0.2
93.4 ± 0.1
47.1 ± 7.9

Figure 9. NLC Particle Size Distribution by Intensity
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Figure 10. SLN vs. NLC Size Distributions by Intensity
Hot melt cast films demonstrated assay results of 76.3 ± 4.1%. Particle
size, polydispersity index, zeta potential, and entrapment efficiency are parameters
designed more for nanoparticle systems and were not evaluated with the hot melt cast
films. Drug release across Spectra/Por® membranes was also not evaluated with the
films.

3.2 Corneal Permeability Studies:
All samples were analyzed via UV analysis at a wavelength of 369 nm, at
which the standard calibration curve had an R2 value of 0.9989. TGA data indicated that
physical mixtures were stable under the utilized processing temperature. Permeability
across the rabbit cornea for quercetin films, NLCs, and control are shown in Figures 11,
12, and 13, respectively.
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Permeability of Quercetin Films
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Figure 11. Permeability of Quercetin Films
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Figure 12. Permeability of Quercetin NLCs
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Permeability of Quercetin Control
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Figure 13. Permeability of Quercetin Control
The results from the permeability studies, in terms of rate, flux, and
permeability, are summarized in Table 5 and Figure 14. Transcorneal flux, which is the
amount of drug that crosses the cornea per minute per area squared (in this case, the area
of the cornea is 0.636 cm), of quercetin control, NLCs, and films were 0.026 ± 0.002,
0.036 ± 0.006, and 0.144 ± 0.009, respectively. Permeability was calculated as flux
normalized by assay.

Table 5. Results for Permeability Studies (Rate, Flux, Permeability)
Rate (µg/min)

Flux (µg/min/cm2)

Control

0.0165 ± 0.002

0.0260 ± 0.002

Permeability X 106
(cm/sec)
0.135 ± 0.012

NLCs

0.0227 ± 0.004

0.0357 ± 0.006

0.186 ± 0.030

Films

0.1435 ± 0.006

0.1435 ± 0.009

0.747 ± 0.047
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Transcorneal Permeability of Quercetin in Different
Formulations
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Figure 14. Transcorneal Permeability of Quercetin in Different Formulations
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4. DISCUSSION:
The goal parameters for the nanoparticle formulations were to have small
particle sizes, low polydispersity index, and high magnitude of zeta potential. Both the
solid lipid nanoparticles and the nanostructured lipid carriers successfully met and fit well
within these goal parameters. Particle sizes for both formulations were well below 500
nm. The peak of the particle size distribution for the NLC formulation was higher and
narrower compared to the peak for the SLN formulation, as the intensity was noticeably
greater and the particle sizes were less variable. Polydispersity indices for both were
close to zero (0), which is the most ideal polydispersity index in order to have a
completely uniform formulation. Zeta potentials for both were relatively high in
magnitude as well (between -10 and -20 mV). Both entrapment efficiencies were at least
90% or higher. Drug releases across the Spectra/Por® membrane for both formulations,
on the other hand, were relatively low (around 30-50%). When comparing assays for all
three formulations (SLNs, NLCs, and films), film assay results were the lowest (by 2%),
and NLCs were the highest (by about 8%), with SLNs in between the two.
In all regards, the NLC formulation had better physicochemical
characteristics compared to the SLN formulation. This is due to the nature of the lipid
matrix shells of the nanoparticles. Because solid lipid nanoparticle formulations use only
solid lipids, the matrix shells are completely solid and continuous, which has limited
permeability. Not only does this affect how much drug can be encapsulated in the
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nanoparticles, but it also affects how the drug diffuses out of the nanoparticles.
Specifically, this structure results in a relatively low drug load, limited drug release, and
drug expulsion during storage. With nanostructured lipid carriers, on the other hand, the
incorporation of a liquid lipid to the solid lipid matrix results in a disrupted and highly
permeable nanoparticle shell. This structure allows for a higher drug load, greater drug
release, and long term drug stability. Thus, from these differences (summarized in Figure
15), we would expect to see that the NLC formulation would show better characteristics
than the SLN formulation, which it did.

Figure 15. Advantages of NLC Structure over SLN Structure
Source: Beloqui A, Solinis MA, Rodríguez-Gascón A, Almeida AJ, Préat V.
Nanostructured lipid carriers: promising drug delivery systems for future clinics.
Nanomedicine: Nanotechnology, Biology and Medicine 2016; 12:143-161.
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To compare how well quercetin permeates from the hot melt cast film
across corneas as opposed to permeation from the nanoparticles, we used a control of
pure quercetin in addition to the NLC formulation, which was chosen because it
demonstrated better parameters and physicochemical characteristics compared to the
SLNs. The three main parameters tested in the permeability studies were rate, flux, and
permeability. Rate was determined by how much drug, in micrograms (μg), crossed the
cornea from the donor to the receiver cells, per minute, with concentrations extrapolated
from the calibration curve based on the absorbance of the samples. The rate of drug
release permeation for the control was the slowest, and the rate for the films was the
highest by a significant margin (7-14x higher), with the rate of the NLCs in between the
two. Flux was calculated as the amount of drug in micrograms that crosses the cornea per
minute per area squared (area = 0.636 cm). Again, the flux for the control was the lowest,
and the flux for the films was the highest by a good margin (4-5x higher). Flux for NLCs
was in between the other two flux values. Lastly, permeability was calculated as flux
normalized by assay and reported as centimeters per second. These results showed the
same trends as with the other two parameters. The permeability of the control across the
cornea was the lowest, the permeability of the drug from the NLCs was second highest,
and the permeability of the drug from the films was the highest, once again by a good
margin (4-6x higher).
In total, both formulations (NLCs and films) were more successful
compared to the control in drug permeability across the cornea. However, the hot melt
cast film formulation showed significantly better parameters in all respects compared to
both the control and the NLC formulation.
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5. CONCLUSION:
Vision problems have become an issue that progressively affects more and
more people each year. With age and prolonged exposure to excessive amounts of
reactive oxidative species comes increased potential for retinal degeneration, and
consequently, vision impairment and/or loss. To protect against this, antioxidants can be
used to neutralize the reactive oxidative species and inhibit excess production by not only
scavenging ROS, but also by mopping up the metal ions that catalyze their production,
thereby limiting the amount of ROS in the body. One such antioxidant is quercetin, a
bioflavonoid that is found commonly in many foods and that exhibits strong antioxidant
properties, among many other potential clinically beneficial uses.
Ocular drug delivery to the back of the eye is difficult, and many barriers
must be overcome for successful drug delivery. Specialized drug delivery systems must
be employed in such cases. Among these are nanoparticle emulsions, such as solid lipid
nanoparticles and nanostructured lipid carriers, as well as hot melt cast films. These
delivery systems have been demonstrated in many studies to be successful in delivering
drugs to the eye, and they have the added benefit of high patient compliance, compared to
other systems, such as intravitreal injections, which are successful but have less patient
compliance.
Solid lipid nanoparticles, nanostructured lipid carriers, and hot melt cast
films were employed in this study in hopes to be able to successfully deliver quercetin to
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the back of the eye where it can act on the retina and protect it from degeneration by
damage from reactive oxidative species. Upon optimization and characterization,
quercetin nanoparticles were successfully prepared with a good particle size distribution
and other physicochemical parameters. Further, in-vitro release and permeability values
demonstrate that nanoparticles can be successfully employed for delivery of quercetin
into the eye through the topical route of administration. The hot melt cast films were also
demonstrated to have good release and permeability profiles. In fact, there was a
significant enhancement of transcorneal permeability of quercetin films compared to the
control and nanoparticles. These results demonstrate that hot melt cast films can also be
successfully employed for delivery of quercetin into the eye through the topical route of
administration and may be a better delivery system for quercetin administration
compared to the nanoparticles.
Future direction for this research includes in-vivo testing of these drug
delivery systems. Specifically, drug delivery in live animals can be performed to test
permeability and absorption across corneas under physiologic conditions. A long term
study can also be performed to test the extent of retinal neuroprotection that quercetin
may have in protecting against damage from reactive oxidative species and consequent
vision impairment.
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